datma Launches Free Tool for Pharma to Assess Biomarker Coverage in Federated RWD
datma, a software company based in Beaverton, Oregon, focused on privacy-preserving federated data infrastructure, has launched the Federated Biomarker Explorer—a free-to-access tool designed to help pharmaceutical teams evaluate biomarker coverage across its distributed real-world data network before entering into formal agreements. Founded in 2016, datma enables structured analysis across health systems and labs without transferring sensitive patient-level data.
datma's explorer tool
The new application provides aggregate, cohort-level insights on biomarker presence, filterable by clinical and demographic attributes. Teams can assess feasibility without requiring IT support, contracting, or data integration.
"Pharma teams often find themselves committing time and resources into exploratory conversations or technical scoping before they can even determine whether a dataset is relevant,” said Robin Edison, VP of Product at datma. “This tool lets users quickly answer the question: is this data feasible for my use case?"
Built on the company’s federated platform, datma.FED, the tool allows users to proceed—if aligned—with secure data linkage and overlap analysis, all without centralizing data. CEO Noah Nasser emphasized that the platform is designed to give teams upfront clarity, reducing the friction and delays often tied to traditional data collaboration models.
Topics: AI & Digital
